Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA.
Circ Heart Fail. 2013 Jul;6(4):727-32. doi: 10.1161/CIRCHEARTFAILURE.112.000265. Epub 2013 Jun 14.
Hospital readmission is an important clinical outcome of patients with heart failure. Its relation to length of stay for the initial hospitalization is not clear.
We used hierarchical modeling of data from a clinical trial to examine variations in length of stay across countries and across hospitals in the United States and its association with readmission within 30 days of randomization. Main outcomes included associations between country-level length of stay and readmission rates, after adjustment for patient-level case mix; and associations between length of stay and readmission rates across sites in the United States. Across 27 countries with 389 sites and 6848 patients, mean length of stay ranged from 4.9 to 14.6 days (6.1 days in the United States). Rates of all-cause readmission ranged from 2.5% to 25.0% (17.8% in the United States). There was an inverse correlation between country-level mean length of stay and readmission (r=-0.52; P<0.01). After multivariable adjustment, each additional inpatient day across countries was associated with significantly lower risk of all-cause readmission (odds ratio, 0.86; 95% confidence interval, 0.75-0.98; P=0.02) and heart failure readmission (odds ratio, 0.79; 95% confidence interval, 0.69-0.99; P=0.03). Similar trends were observed across US study sites concerning readmission for any cause (odds ratio, 0.92; 95% confidence interval, 0.85-1.00; P=0.06) and readmission for heart failure (odds ratio, 0.90; 95% confidence interval, 0.80-1.01; P=0.07). Across countries and across US sites, longer median length of stay was independently associated with lower risk of readmission.
Countries with longer length of stay for heart failure hospitalizations had significantly lower rates of readmission within 30 days of randomization. These findings may have implications for developing strategies to prevent readmission, defining quality measures, and designing clinical trials in acute heart failure.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.
心力衰竭患者的住院再入院是一个重要的临床结局。其与初次住院的住院时间之间的关系尚不清楚。
我们使用临床试验数据的层次建模,研究了不同国家和美国不同医院之间的住院时间差异及其与随机分组后 30 天内再入院的关系。主要结局包括调整患者病例组合后,国家层面的住院时间与再入院率之间的关系;以及美国各研究地点之间的住院时间与再入院率之间的关系。在 27 个国家的 389 个地点和 6848 名患者中,平均住院时间为 4.9 至 14.6 天(美国为 6.1 天)。全因再入院率为 2.5%至 25.0%(美国为 17.8%)。国家层面的平均住院时间与再入院率呈负相关(r=-0.52;P<0.01)。经过多变量调整,各国每增加一天住院时间,全因再入院的风险显著降低(比值比,0.86;95%置信区间,0.75-0.98;P=0.02)和心力衰竭再入院(比值比,0.79;95%置信区间,0.69-0.99;P=0.03)。在美国的研究地点,任何原因导致的再入院(比值比,0.92;95%置信区间,0.85-1.00;P=0.06)和心力衰竭再入院(比值比,0.90;95%置信区间,0.80-1.01;P=0.07)也观察到类似的趋势。在国家层面和美国的研究地点,较长的中位住院时间与再入院风险降低独立相关。
心力衰竭住院时间较长的国家,随机分组后 30 天内的再入院率显著降低。这些发现可能对制定预防再入院的策略、定义质量指标和设计急性心力衰竭的临床试验具有重要意义。